Innovent Biologics, Inc. (OTCMKTS:IVBXF) Short Interest Update

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a large decline in short interest during the month of December. As of December 31st, there was short interest totaling 97,715 shares, a decline of 32.3% from the December 15th total of 144,277 shares. Based on an average trading volume of 50,816 shares, the days-to-cover ratio is currently 1.9 days. Based on an average trading volume of 50,816 shares, the days-to-cover ratio is currently 1.9 days.

Innovent Biologics Price Performance

Shares of OTCMKTS IVBXF opened at $11.17 on Friday. Innovent Biologics has a 12 month low of $3.91 and a 12 month high of $15.12. The business has a fifty day simple moving average of $11.16 and a 200-day simple moving average of $11.64.

Innovent Biologics Company Profile

Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.

The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).